ArticleInfection prevention in practice2026
Association between antimicrobial use and the detection rates of carbapenem-resistant Enterobacterales: long-term surveillance results from a single centre.
Article in Infection prevention in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between clinically relevant antibiotic-resistant biliary colonization and liver-specific complications following perihilar cholangiocarcinoma resection.Langenbeck's archives of surgery · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenems are vital for treating Enterobacterales infections. However, the emergence of carbapenem-resistant Enterobacterales (CRE), mediated by carbapen-emases or otherwise, has become a global concern due to increased morbidity and mortality. In Japan, metallo-β-lactamase was found to be the predominant carbapenemase, notably imipenemase. Both carbapenem-susceptible and carbapenem-resistant strains of carbapenemase-producing Enterobacterales exist, which complicates the identification of carbapenemase production through susceptibility testing alone. Infection control measures, such as contact precautions and antimicrobial stewardship, are recommended to combat resistant strains. Since carbapenem use is a risk factor for resistance, reducing its consumption is a key strategy for resistance management. Aim: To elucidate the impact of antimicrobial use on CRE detection rates and antimicrobial resistance trends and to propose a risk assessment framework for antimicrobial resistance surveillance. Methods: We analysed the relationship between antimicrobial use density (AUD), days of therapy (DOT) and CRE detection among inpatients at Toho University Omori Medical Centre between 2014 and 2022. Results: Overall, AUD and DOT increased, notably for piperacillin/tazobactam (TZP), cefmetazole, ceftriaxone (CRO) and cefepime. Conversely, AUD and DOT for flomoxef, cefoperazone/sulbactam, cefozopran, ciprofloxacin, levofloxacin, doripenem, aztreonam and fosfomycin decreased. AUD of meropenem (MEM) increased, but its overall proportion decreased. TZP and CRO correlated with resistance rates, while MEM did not. Carbapenemase-producing carbapenem-non-susceptible Enterobacterales (CP-CNSE) detection was associated with TZP usage, and non-carbapenemase-producing (NCP)-CNSE detection correlated with overall AUD, TZP, and CRO use. Conclusion: Reducing TZP and cephalosporin usage, in addition to carbapenems, is crucial for preventing resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.